Celltrion and Teva announced today that the FDA has accepted for review the companies’ Biologics License Application (BLA) for CT-P6, a proposed trastuzumab (Herceptin) biosimilar.
Celltrion and Teva announced today that the FDA has accepted for review the companies’ Biologics License Application (BLA) for CT-P6, a proposed trastuzumab (Herceptin) biosimilar.
Woo Sung Kee, CEO of Celltrion, said, “Following on the heels of our global success with…our infliximab biosimilar, which has brought affordable and effective biologic treatment to many patients around the world with proven similarity of quality, efficacy and safety to the reference product, we are confident to submit a comprehensive package of quality, nonclinical and clinical data of CT-P6 for FDA review.” Teva’s senior vice president and general manager of the company’s oncology division, Paul Rittman, added, “we look forward to the opportunity to leverage Teva’s strong legacy and US commercial presence in [oncology] to bring additional biosimilar treatment options to patients.”
The BLA for CT-P6 includes efficacy, safety, immunogenicity, pharmacodynamic, and pharmacokinetic data from trials conducted in over 500 patients in 22 countries. A recent phase 3 equivalence trial of CT-P6 as a neoadjuvant treatment in human epidermal growth factor receptor 2-positive early breast cancer demonstrated equivalent efficacy of the proposed biosimilar to the reference trastuzumab, with a similar proportion of patients achieving pathological complete response with CT-P6 and the reference trastuzumab.
Today’s BLA is the second in as many months from the Celltrion and Teva partnership; the companies announced in June that the FDA had accepted for review a BLA for CT-P10, a proposed biosimilar to rituximab (Rituxan). A 2016 partnership announcement between the 2 companies included a deal to commercialize CT-P6 and CT-P10 in the United States and Canada. Celltrion says that it expects FDA regulatory action on both applications in the first half of 2018.
If CT-P6 and CT-P10 are both approved, the companies will be poised to compete for shares of the substantial—and growing—markets for trastuzumab and rituximab. Sales of the reference trastuzumab hit $6.75 billion in 2016 (up 3.7% from 2015), and sales of rituximab totaled $8.58 billion (up by 2.7%).
The Teva—Celltrion partnership may well challenge the Mylan–Biocon partnership for market share of trastuzumab—the latter’s MYL-1401O, another proposed biosimilar to the reference Herceptin, is expected to receive FDA approval in September after a unanimous recommendation by the FDA’s Oncologic Drugs Advisory Committee earlier this month.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.